The combination of 9p21.3 genotype and biomarker profile improves a peripheral artery disease risk prediction model

Vascular Medicine (United Kingdom)

Volumn 19, Issue 1, 2014, Pages 3-8

  Downing, Kelly P ^a   Nead, Kevin T ^b   Kojima, Yoko ^a   Assimes, Themistocles ^b   Maegdefessel, Lars ^c   Quertermous, Thomas ^b   Cooke, John P ^b   Leeper, Nicholas J ^a  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

biomarkers; genomics; peripheral artery disease; risk factors

Indexed keywords

BIOMARKERS; GENOMICS; PERIPHERAL ARTERY DISEASE; RISK FACTORS;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHROMOSOMES, HUMAN, PAIR 9; CYSTATIN C; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOTYPE; HUMANS; MALE; MIDDLE AGED; PERIPHERAL ARTERIAL DISEASE; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 84894490716     PISSN: 1358863X     EISSN: 14770377     Source Type: Journal    
DOI: 10.1177/1358863X13514791     Document Type: Article

References (39)

1. Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation. 1985 ; 71: 510-515
2. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001 ; 286: 1317-1324
3. Meijer WT, Hoes AW, Rutgers D, Bots ML, Hofman A, Grobbee DE. Peripheral arterial disease in the elderly: The Rotterdam Study. Arterioscler Thromb Vasc Biol. 1998 ; 18: 185-192
4. Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007 ; 297: 1197-1206
5. Anand SS, Kundi A, Eikelboom J, Yusuf S. Low rates of preventive practices in patients with peripheral vascular disease. Can J Cardiol. 1999 ; 15: 1259-1263
6. Oka RK, Umoh E, Szuba A, Giacomini JC, Cooke JP. Suboptimal intensity of risk factor modification in PAD. Vasc Med. 2005 ; 10: 91-96
7. Valentijn TM, Stolker RJ. Lessons from the REACH Registry in Europe. Curr Vasc Pharmacol. 2012 ; 10: 725-727
8. McDermott MM, Mehta S, Ahn H, Greenland P. Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. J Gen Intern Med. 1997 ; 12: 209-215
9. Sadrzadeh Rafie AH, Stefanick ML, Sims ST, et al. Sex differences in the prevalence of peripheral artery disease in patients undergoing coronary catheterization. Vasc Med. 2010 ; 15: 443-450
10. Fowkes FG, Housley E, Macintyre CC, Prescott RJ, Ruckley CV. Variability of ankle and brachial systolic pressures in the measurement of atherosclerotic peripheral arterial disease. J Epidemiol Community Health. 1988 ; 42: 128-133
11. Fung ET, Wilson AM, Zhang F, et al. A biomarker panel for peripheral arterial disease. Vasc Med. 2008 ; 13: 217-224
12. Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007 ; 49: 1982-1988
13. Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation. 1997 ; 96: 44-49
14. Pradhan AD, Shrivastava S, Cook NR, Rifai N, Creager MA, Ridker PM. Symptomatic peripheral arterial disease in women: nontraditional biomarkers of elevated risk. Circulation. 2008 ; 117: 823-831
15. Wilson AM, Kimura E, Harada RK, et al. Beta2-microglobulin as a biomarker in peripheral arterial disease: proteomic profiling and clinical studies. Circulation. 2007 ; 116: 1396-1403
16. Leeper NJ, Kullo IJ, Cooke JP. Genetics of peripheral artery disease. Circulation. 2012 ; 125: 3220-3228
17. Hamburg NM, Leeper NJ. Therapeutic potential of modulating microRNA in peripheral arterial disease. Curr Vasc Pharmacol. :
18. Duval S, Massaro JM, Jaff MR, et al. An evidence-based score to detect prevalent peripheral artery disease (PAD). Vasc Med. 2012 ; 17: 342-351
19. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med. 1994 ; 330: 1041-1046
20. Helgadottir A, Thorleifsson G, Manolescu A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007 ; 316: 1491-1493
21. McPherson R, Pertsemlidis A, Kavaslar N, et al. A common allele on chromosome 9 associated with coronary heart disease. Science. 2007 ; 316: 1488-1491
22. Helgadottir A, Thorleifsson G, Magnusson KP, et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet. 2008 ; 40: 217-224
23. Wilson AM, Sadrzadeh-Rafie AH, Myers J, et al. Low lifetime recreational activity is a risk factor for peripheral arterial disease. J Vasc Surg. 2011 ; 54: 427 432.e1-432 4
24. Nead KT, Zhou MJ, Caceres RD, et al. Usefulness of the addition of beta-2-microglobulin, cystatin C and C-reactive protein to an established risk factors model to improve mortality risk prediction in patients undergoing coronary angiography. Am J Cardiol. 2013 ; 111: 851-856
25. Ding H, Xu Y, Wang X, et al. 9p21 is a shared susceptibility locus strongly for coronary artery disease and weakly for ischemic stroke in Chinese Han population. Circ Cardiovasc Genet. 2009 ; 2: 338-346
26. Heckman MG, Soto-Ortolaza AI, Diehl NN, et al. Genetic variants associated with myocardial infarction in the PSMA6 gene and Chr9p21 are also associated with ischaemic stroke. Eur J Neurol. 2013 ; 20: 300-308
27. Shiffman D, O'Meara ES, Rowland CM, et al. The contribution of a 9p21.3 variant, a KIF6 variant, and C-reactive protein to predicting risk of myocardial infarction in a prospective study. BMC Cardiovasc Disord. 2011 ; 11: 10
28. Murabito JM, White CC, Kavousi M, et al. Association between chromosome 9p21 variants and the ankle-brachial index identified by a meta-analysis of 21 genome-wide association studies. Circ Cardiovasc Genet. 2012 ; 5: 100-112
29. Nead KT, Zhou M, Diaz Caceres R, Olin JW, Cooke JP, Leeper NJ. The Walking Impairment Questionnaire improves mortality risk prediction models in a high-risk cohort independent of peripheral arterial disease status. Circ Cardiovasc Qual Outcomes. 2013 ; 6: 255-261
30. McDermott MM, Liu K, Guralnik JM, Martin GJ, Criqui MH, Greenland P. Measurement of walking endurance and walking velocity with questionnaire: validation of the walking impairment questionnaire in men and women with peripheral arterial disease. J Vasc Surg. 1998 ; 28: 1072-1081
31. Regensteiner JG, Steiner JF, Hiatt WR. Exercise training improves functional status in patients with peripheral arterial disease. J Vasc Surg. 1996 ; 23: 104-115
32. Pencina MJ, D'Agostino RB, D'Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008 ; 27: 157-172
33. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) - a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009 ; 42: 377-381
34. Nead KT, Cooke JP, Olin JW, Leeper NJ. Alternative ankle-brachial index method identifies additional at-risk individuals. J Am Coll Cardiol. 2013 ; 62: 553-559
35. Meijer WT, Grobbee DE, Hunink MG, Hofman A, Hoes AW. Determinants of peripheral arterial disease in the elderly: the Rotterdam study. Arch Intern Med. 2000 ; 160: 2934-2938
36. Knowles JW, Assimes TL, Li J, Quertermous T, Cooke JP. Genetic susceptibility to peripheral arterial disease: a dark corner in vascular biology. Arterioscler Thromb Vasc Biol. 2007 ; 27: 2068-2078
37. Zintzaras E, Zdoukopoulos N. A field synopsis and meta-analysis of genetic association studies in peripheral arterial disease: The CUMAGAS-PAD database. Am J Epidemiol. 2009 ; 170: 1-11
38. Leeper NJ, Raiesdana A, Kojima Y, et al. Loss of CDKN2B promotes p53-dependent smooth muscle cell apoptosis and aneurysm formation. Arterioscler Thromb Vasc Biol. 2013 ; 33: e1 - e10
39. Mahoney EM, Wang K, Cohen DJ, et al. One-year costs in patients with a history of or at risk for atherothrombosis in the United States. Circ Cardiovasc Qual Outcomes. 2008 ; 1: 38-45